Latest & greatest articles for bupropion

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on bupropion or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on bupropion and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for bupropion

41. The cost utility of bupropion in smoking cessation health programs: simulation model results for Sweden Full Text available with Trip Pro

The cost utility of bupropion in smoking cessation health programs: simulation model results for Sweden The cost utility of bupropion in smoking cessation health programs: simulation model results for Sweden The cost utility of bupropion in smoking cessation health programs: simulation model results for Sweden Bolin K, Lindgren B, Willers S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study compared the use of bupropion tablets (Zyban, GlaxoSmithKline), two 150-mg tablets per day, with nicotine replacement therapy (patches or gum) as part of a smoking cessation programme. Type of intervention Public health intervention: smoking cessation programme. Economic study type Cost-utility analysis. Study population The study

2006 NHS Economic Evaluation Database.

42. Major depressive disorder: similar remission rates with bupropion, sertraline, or venlafaxine following treatment switch from citalopram

Major depressive disorder: similar remission rates with bupropion, sertraline, or venlafaxine following treatment switch from citalopram Major depressive disorder: similar remission rates with bupropion, sertraline, or venlafaxine following treatment switch from citalopram | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies (...) , please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Major depressive disorder: similar remission rates with bupropion, sertraline, or venlafaxine following treatment

2006 Evidence-Based Mental Health

43. Conversion from sustained-release to immediate-release bupropion: patient tolerability and economic impact

Conversion from sustained-release to immediate-release bupropion: patient tolerability and economic impact Conversion from sustained-release to immediate-release bupropion: patient tolerability and economic impact Conversion from sustained-release to immediate-release bupropion: patient tolerability and economic impact Mayo J L, Cahill G M, Lott R S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains (...) a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study compared the use of a single dose of sustained-release bupropion 200 mg (GlaxoSmithKline) versus a single dose of immediate-release bupropion 150 mg (generic). Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised patients from the authors

2005 NHS Economic Evaluation Database.

44. Review: nortriptyline and bupropion each increase smoking cessation rates Full Text available with Trip Pro

Review: nortriptyline and bupropion each increase smoking cessation rates Review: nortriptyline and bupropion each increase smoking cessation rates | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username (...) * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: nortriptyline and bupropion each increase smoking cessation rates Article Text Therapeutics Review: nortriptyline and bupropion each increase smoking cessation rates Free Charles J Bentz , MD, FACP Statistics from Altmetric.com Hughes JR

2005 Evidence-Based Medicine

45. Are there gender differences in smoking cessation, with and without bupropion: pooled- and meta-analyses of clinical trials of Bupropion SR

Are there gender differences in smoking cessation, with and without bupropion: pooled- and meta-analyses of clinical trials of Bupropion SR Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2004 DARE.

46. Sustained-release bupropion for smoking cessation in African Americans: a randomized controlled trial. (Abstract)

Sustained-release bupropion for smoking cessation in African Americans: a randomized controlled trial. African Americans disproportionately experience greater smoking attributable morbidity and mortality. Few clinical trials for smoking cessation in African Americans have been conducted, despite a different profile of both smoking and quitting patterns.To compare a sustained-release form of bupropion hydrochloride (bupropion SR) with placebo for smoking cessation among African (...) Americans.Randomized, double-blind, placebo-controlled trial conducted from February 11, 1999, to December 8, 2000, of 600 African American adults treated at a community-based health care center. Volunteers, who smoked 10 or more cigarettes per day were recruited by targeted media and health care professionals.Participants were randomly assigned to receive 150 mg of bupropion SR (n = 300) or placebo (n = 300) twice daily for 7 weeks. Brief motivational counseling was provided in-person at baseline, quit day, weeks

2002 JAMA Controlled trial quality: predicted high

47. The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation: a systematic review and economic evaluation

The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation: a systematic review and economic evaluation The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation: a systematic review and economic evaluation The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation: a systematic review and economic evaluation Woolacott (...) N F, Jones L, Forbes C A, Mather L C, Sowden A J, Song F J, Raftery J P, Aveyard P N, Barton P M Authors' objectives To assess the clinical effectiveness, cost-effectiveness and adverse events of bupropion sustained-release (BSR) and nicotine replacement therapy (NRT) for smoking cessation. Searching The authors searched a number of different databases and websites up to May 2001 (a detailed search strategy was provided). The bibliographies of retrieved articles and submissions were also checked

2002 DARE.

48. Cardiotoxicity following bupropion overdose

Cardiotoxicity following bupropion overdose Cardiotoxicity following bupropion overdose Cardiotoxicity following bupropion overdose Druteika D, Zed P J Authors' objectives To determine whether an overdose of bupropion has been associated with cardiotoxicity. Searching MEDLINE (from 1966 to January 2002), EMBASE (from 1980 to January 2002), Current Contents (January 2002) and PubMed (January 2002) were searched. The keywords used in the search included 'bupropion', 'overdose (drug (...) )', 'intoxication', 'poisoning' and 'acute ingestion'. The reference lists from identified studies and reviews were also examined. Only studies published in the English language were included. Study selection Study designs of evaluations included in the review Studies of any design were eligible for inclusion. The included studies were retrospective case series (cases reported to six U.S. poison centres between 1989 and 1991) and case reports. Specific interventions included in the review Studies of bupropion

2002 DARE.

49. Guidance on the use of nicotine replacement therapy (NRT) and bupropion for smoking cessation

Guidance on the use of nicotine replacement therapy (NRT) and bupropion for smoking cessation Guidance on the use of nicotine replacement therapy (NRT) and bupropion for smoking cessation Guidance on the use of nicotine replacement therapy (NRT) and bupropion for smoking cessation National Institute for Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database (...) . Citation National Institute for Clinical Excellence. Guidance on the use of nicotine replacement therapy (NRT) and bupropion for smoking cessation. London: National Institute for Clinical Excellence (NICE). Technology Appraisal Guidance 39. 2002 Authors' objectives To provide guidance on the use of nicotine replacement therapy (NRT) and bupropion for smoking cessation. Authors' conclusions Guidance 1.1 Nicotine replacement therapy (NRT) and bupropion are recommended for smokers who have expressed

2002 Health Technology Assessment (HTA) Database.

50. The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation: a systematic review and economic evaluation

The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation: a systematic review and economic evaluation The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation: a systematic review and economic evaluation The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation: a systematic review and economic evaluation Woolacott (...) N F, Jones L, Forbes C A, Mather L C, Sowden A J, Song F J, Raftery J P, Aveyard P N, Hyde C J, Barton P M Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Woolacott N F, Jones L, Forbes C A, Mather L C, Sowden A J, Song F J, Raftery J P, Aveyard P N, Hyde C J, Barton P M. The clinical effectiveness and cost-effectiveness of bupropion

2002 Health Technology Assessment (HTA) Database.

51. Bupropion (Zyban) in smoking cessation

Bupropion (Zyban) in smoking cessation Bupropion (Zyban) in smoking cessation We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Swedish Agency for Health Technology Assessment and Assessment of Social Services Bupropion (Zyban) in smoking cessation Share: Reading time approx. 5 minutes This document was published more than 2 years ago. The nature of the evidence may have changed. Findings by SBU Alert Version: 2 Technology (...) and target group Bupropion (Zyban), the first drug registered for smoking cessation that does not contain nicotine, was introduced in Sweden during 2000. Originally, bupropion is an antidepressant. It is a prescription drug, but not covered under the drug benefit. The target group for treatment with bupropion includes smokers who have not succeeded with other treatment methods for smoking cessation. Patient benefit The effects of bupropion, in combination with individual support, have been studied

2002 Swedish Council on Technology Assessement

52. Summaries for patients. Bupropion to prevent relapse in people who quit cigarette smoking. (Abstract)

Summaries for patients. Bupropion to prevent relapse in people who quit cigarette smoking. 11575280 2001 10 04 2017 11 16 0003-4819 135 6 2001 Sep 18 Annals of internal medicine Ann. Intern. Med. Summaries for patients. Bupropion to prevent relapse in people who quit cigarette smoking. S-40 eng Clinical Trial Journal Article Multicenter Study Randomized Controlled Trial United States Ann Intern Med 0372351 0003-4819 0 Delayed-Action Preparations 01ZG3TPX31 Bupropion AIM IM Adult Bupropion

2001 Annals of Internal Medicine Controlled trial quality: uncertain

53. Economic model of sustained-release bupropion hydrochloride in health plan and work site smoking-cessation programs

Economic model of sustained-release bupropion hydrochloride in health plan and work site smoking-cessation programs Economic model of sustained-release bupropion hydrochloride in health plan and work site smoking-cessation programs Economic model of sustained-release bupropion hydrochloride in health plan and work site smoking-cessation programs Halpern M T, Khan Z M, Young T L, Battista C Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion (...) on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of sustained-release (SR) bupropion hydrochloride in health plan and work site smoking-cessation programmes. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised a hypothetical cohort of 100,000 employees

2000 NHS Economic Evaluation Database.

54. Cost-benefit analysis of sustained-release bupropion, nicotine patch, or both for smoking cessation Full Text available with Trip Pro

Cost-benefit analysis of sustained-release bupropion, nicotine patch, or both for smoking cessation Cost-benefit analysis of sustained-release bupropion, nicotine patch, or both for smoking cessation Cost-benefit analysis of sustained-release bupropion, nicotine patch, or both for smoking cessation Nielsen K, Fiore M C Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods (...) , the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Sustained-release bupropion, nicotine patch, or both for smoking cessation. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population consisted of smokers who were enrolled on a smoking cessation programme, the details of which were reported in a study published in 1999. Setting The study setting

2000 NHS Economic Evaluation Database.

55. New Drugs VI ? Rosiglitazone (Avandia®), Tolterodine (Detrol®), Bupropion (Wellbutrin SR®, Zyban®), Doxazosin (Cardura®)

New Drugs VI ? Rosiglitazone (Avandia®), Tolterodine (Detrol®), Bupropion (Wellbutrin SR®, Zyban®), Doxazosin (Cardura®) [44] New Drugs VII – Mirtazapine (Remeron®), Salmon-Calcitonin Nasal Spray (Miacalcin®), Gatifloxacin (Tequin®), Moxifloxacin | Therapeutics Initiative Independent Healthcare Evidence > > [44] New Drugs VII – Mirtazapine (Remeron®), Salmon-Calcitonin Nasal Spray (Miacalcin®), Gatifloxacin (Tequin®), Moxifloxacin Mirtazapine (Remeron ® ) Approved indication: “Symptomatic

2000 Therapeutics Letter

56. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. Full Text available with Trip Pro

A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. Use of nicotine-replacement therapies and the antidepressant bupropion helps people stop smoking. We conducted a double-blind, placebo-controlled comparison of sustained-release bupropion (244 subjects), a nicotine patch (244 subjects), bupropion and a nicotine patch (245 subjects), and placebo (160 subjects) for smoking cessation. Smokers with clinical depression were excluded. Treatment (...) consisted of nine weeks of bupropion (150 mg a day for the first three days, and then 150 mg twice daily) or placebo, as well as eight weeks of nicotine-patch therapy (21 mg per day during weeks 2 through 7, 14 mg per day during week 8, and 7 mg per day during week 9) or placebo. The target day for quitting smoking was usually day 8.The abstinence rates at 12 months were 15.6 percent in the placebo group, as compared with 16.4 percent in the nicotine-patch group, 30.3 percent in the bupropion group (P

1999 NEJM Controlled trial quality: predicted high

57. A comparison of sustained-release bupropion and placebo for smoking cessation. Full Text available with Trip Pro

A comparison of sustained-release bupropion and placebo for smoking cessation. Trials of antidepressant medications for smoking cessation have had mixed results. We conducted a double-blind, placebo-controlled trial of a sustained-release form of bupropion for smoking cessation. We excluded smokers with current depression, but not those with a history of major depression. The 615 subjects were randomly assigned to receive placebo or bupropion at a dose of 100, 150, or 300 mg per day for seven (...) (a gain of 2.9 kg in the placebo group, 2.3 kg in 100-mg and 150-mg groups, and 1.5 kg in the 300-mg group; P= 0.02). No effects of treatment were observed on depression scores as measured serially by the Beck Depression Inventory. Thirty-seven subjects stopped treatment prematurely because of adverse events; the frequency was similar among all groups.A sustained-release form of bupropion was effective for smoking cessation and was accompanied by reduced weight gain and minimal side effects. Many

1997 NEJM Controlled trial quality: predicted high